$18.82
-6.8%Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Chief Commercial Officer
Chief Financial Officer
Compensation
$530,176
Chief Information Officer
Co-Founder, General Counsel, Chief Administrative Officer, Secretary & Director
Compensation
$498,289
Founder, President, Chief Executive Officer & Director
Compensation
$757,564
Senior Vice President of Marketing
Senior Vice President of Operations
Senior Vice President of Research & Development
Vice President of Investor Relations
During the last 12 months, insiders have purchased $200K and sold $2.09M worth of KMTS shares, resulting in $1.89M of net selling activity.
10.0K
199.80K
38.2K
772.20K
-572K
-$572K
0
0.00
52.1K
1.32M
-1.3M
-$1.32M
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
Cohen Raymond W
Director
$200K
Webster Brian Daniel
Director, Officer: See Remarks
$1.81M
Umberger Traci S
Director, Officer: See Remarks
$280K
Strong bearish signal with $1.89M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
KMTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | July 22, 2025 | September 03, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.